Prognostic markers to predict efficacy of 5-FU rechallenge as third line chemotherapy in metastatic colorectal cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter I.-J. Chung
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors I.-. Chung1, K. Kim1, H.-. Shim2, J.-. Hwang2, W.K. Bae2, S.-. Cho2
  • 1Chonnam National University Hwasun Hospital, Hwasun-Gun, Republic of Korea, /
  • 2Hematology/Oncology, Chonnam National University Hwasun Hospital, Hwasun-Gun, Republic of Korea, /

Abstract

There is a lack of data about the role of further chemotherapy after standard treatment for metastatic colorectal cancer (mCRC). Rechallenge with a prior chemotherapy could be another option for selected patients to attenuate the tumor progression, however, there is no prognostic makers to select these patients. Therefore, we evaluated early tumor shrinkage (ETS) and depth of response (DoR) as clinical decision parameters, and single-nucleotide polymorphisms (SNPs) as biomarkers to choose patients who may benefit from rechallenging prior chemotherapy.